Business
CytoSorbents develops and sells blood-purification cartridges used in critical care and cardiac surgery.
CytoSorbents' modest blood-purification growth did not stop losses or cash burn, while going-concern doubt, a material weakness and workforce restructuring heightened the financing risk.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 4.1%OK
- Profitability — The net loss narrowed from $20.719M to $8.198MOK
- Cash flow — Free cash flow remained negative, with the outflow narrowing from $14.712M to $12.541MOK
- Margins — Operating margin expanded 643 bps to -39.79%OK
- Accounting — Going-concern warning and control remediationWatch
- Insiders — 3 purchases and 0 salesOK
Where the revenue comes from
Fiscal 2025, as Cytosorbents Corp reports it. History and quarterly detail are in the app.
- Total product sales$37.1M
Leadership changes
From Cytosorbents Corp's own filings, the day they're filed.
- Peter J. Mariani · Chief Financial Officer · departureeff. 2024-08-14
- Kathleen P. Bloch · Chief Financial Officer · departureeff. 2024-08-14
- Mutual Termination · departure
Latest filings
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-07
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cytosorbents Corp, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.